Space Peptides Completes RMB 100 Million Series A Funding Round to Advance AI-Driven Peptide Drug CRDMO Platform

April 2nd News: Space Peptides (Shanghai) Medicine Technology Co., Ltd. announced the completion of its Series A financing round worth hundreds of millions, marking the company's first institutional funding. This round was jointly led by Shenzhen CO-WIN Venture CAPITAL Investment Limited and Nanjing Yongpeptide Private Equity Fund Management Co., Ltd., with participation from Chaoqian Capital.

This round of funding will mainly be used for the upgrade and construction of the company's big data and artificial intelligence center for peptide spatial structures in Shanghai-Switzerland Basel, the preclinical research center in Xiamen, and the production line construction of the peptide CDMO manufacturing base in Taizhou, Jiangsu, thereby further enhancing the company’s capacity to undertake innovative drug CRDMO services.

Space Peptides integrates big data on drug structures with artificial intelligence (AI), focusing on building a one-stop AI-CRDMO service platform for peptides, peptidomimetics, and peptide-drug conjugates (PDC) from new drug discovery (CRO) to industrial production (CMO/CDMO). Space Peptides adopts a co-development model with pharmaceutical companies, providing services such as AI design and synthesis of drug molecules, preclinical animal experiment validation, delivery of patentable preclinical candidate compounds (PCC), and innovative drug clinical trial applications. It also offers active pharmaceutical ingredient (API) production and supply for all stages, including clinical research and large-scale commercialization after drug approval.